Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 141 No. 4546 (2011)

DLG5 P1371Q is associated with inflammatory bowel disease and complementary to R30Q in disease susceptibility

  • Z Lin
  • JP Hegarty
  • A Berg
  • Z Wang
  • Y Wang
  • R Wu
  • AA Kelly
  • LS Poritz
  • WA Koltun
DOI
https://doi.org/10.4414/smw.2011.13290
Cite this as:
Swiss Med Wkly. 2011;141:w13290
Published
07.11.2011

Summary

BACKGROUND AND PURPOSE:The SNP R30Q (rs1248696) within the discs large homolog 5 (DLG5) gene has been associated with inflammatory bowel disease (IBD). In this study, we examined the genetic association of another DLG5 SNP P1371Q (rs2289310) with IBD and its interaction with R30Q in disease susceptibility.

METHODS:A total of 213 IBD patients [106 familial; 59 Crohn’s disease (CD) and 47 ulcerative colitis (UC)] and 107 sporadic [57 CD and 50 UC] were included in this study. Controls included 139 non-diseased family members of IBD patients and 170 unrelated healthy subjects. Genotypes for P1371Q and G1066G polymorphisms were determined by PCR–based RFLP. Epistasis between P1371Q and R30Q in disease susceptibility was analysed using a novel statistical model.

RESULTS:P1371Q was associated with IBD (OR = 2.335, 95% CI = 1.097–4.972, p = 0.0246), however, the synonymous variant G1066G (rs1648234) was not. Gender distribution analysis revealed the A allele of P1371Q was significantly associated with IBD in women (OR = 3.765, 95% CI = 1.307–10.85, p = 0.0095). Modeling interaction between P1371Q and R30Q showed a significant increase in disease association (OR = 2.265, 95% CI = 1.405–3.652, p = 0.0007) incidence for sporadic and familial IBD patients. Further epistatic analysis identified an increased significance in the association of gender with IBD (OR = 4.311, 95% CI = 2.101–8.846, p = 0.0001).

CONCLUSIONS:DLG5 P1371Q was associated with IBD and this association was female-specific. A significant epistatic interaction between P1371Q and R30Q was observed, suggesting that P1371Q is complementary to R30Q, with R30Q exhibiting a dominant effect in IBD susceptibility.

References

  1. Russell RK, Nimmo ER, Satsangi J. Molecular genetics of Crohn’s disease. Curr Opin Genet Dev. 2004;14:264–70.
  2. Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet. 2005;6:376–88.
  3. Achkar JP, Duerr R. The expanding universe of inflammatory bowel disease genetics. Curr Opin Gastroenterol. 2008;24:429–34.
  4. Henckaerts L, Figueroa C, Vermeire S, Sans M. The role of genetics in inflammatory bowel disease. Curr Drug Targets. 2008;9:361–8.
  5. Ishihara S, Aziz MM, Yuki T, Kazumori H, Kinoshita Y. Inflammatory bowel disease: review from the aspect of genetics. J Gastroenterol. 2009;44:1097–108.
  6. Haas SL, Abbatista M, Brade J, Singer MV, Bocker U. Interleukin-18 serum levels in inflammatory bowel diseases: correlation with disease activity and inflammatory markers. Swiss Med Wkly. 2009;139:140–5.
  7. Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn’s disease. Hum Mol Genet. 2005;14:3499–506.
  8. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silvernerg MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461–3.
  9. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207–11.
  10. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39:596–604.
  11. Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007;3:e58.
  12. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.
  13. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet. 2007;39:830–2.
  14. Latiano A, Palmieri O, Corritore G, Valvano MR, Bossa F, Cucchiara S, et al. Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009.
  15. Lees CW, Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol. 2009;3:513–34.
  16. Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36:476–80.
  17. Wakabayashi M, Ito T, Mitsushima M, Aizawa S, Ueda K, Amachi T, Kioka N. Interaction of lp-dlg/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact. J Biol Chem. 2003;278:21709–14.
  18. Humbert P, Russell S, Richardson H. Dlg, Scribble and Lgl in cell polarity, cell proliferation and cancer. Bioessays. 2003;25:542–53.
  19. Daly MJ, Pearce AV, Farwell L, Fisher SA, Latiano A, Prescott NJ, et al. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur J Hum Genet. 2005;13(7):835–9.
  20. Newman WG, Gu X, Wintle RF, Liu X, van Oene M, Amos CI, Siminovitch KA. DLG5 variants contribute to Crohn disease risk in a Canadian population. Hum Mutat. 2006;27:353–8.
  21. Friedrichs F, Brescianini S, Annese V, Latiano A, Berger K, Kugathasan S, et al. Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Hum Genet. 2006;119:305–11.
  22. Friedrichs F, Stoll M. Role of discs large homolog 5. World J Gastroenterol. 2006;12:3651–6.
  23. Vermeire S, Pierik M, Hlavaty T, Claessens G, van Schuerbeeck N, Joossens S, et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn’s disease but not with susceptibility to IBD. Gastroenterol. 2005;129:1845–53.
  24. Lakatos PL, Fischer S, Claes K, Kovacs A, Molnar T, Altorjay I, et al. DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn’s disease. Inflamm Bowel Dis. 2006;12:362–8.
  25. Ferraris A, Torres B, Knafelz D, Barabino A, Lionetti P, de Angelis GL, et al. Relationship between CARD15, SLC22A4/5, and DLG5 polymorphisms and early-onset inflammatory bowel diseases: an Italian multicentric study. Inflamm Bowel Dis. 2006;12:355–61.
  26. Buning C, Geerdts L, Fiedler T, Gentz E, Pitre G, Reuter W, et al. DLG5 variants in inflammatory bowel disease. Am J Gastroenterol. 2006;101:786–92.
  27. Torok HP, Glas J, Tonenchi L, Lohse P, Muller-Myhsok B, Limbersky O, et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn’s disease. Gut. 2005;54:1421–7.
  28. Tremelling M, Waller S, Bredin F, Greenfield S, Parkes M. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. Inflamm Bowel Dis. 2006;12:178–84.
  29. Noble CL, Nimmo ER, Drummond H, Ho GT, Tenesa A, Smith L, et al. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn’s disease. Gastroenterol. 2005;129:1854–64.
  30. Browning BL, Barclay ML, Bingham SA, et al. Gender-stratified analysis of DLG5 R30Q in 4707 Crohn’s disease patients and 4973 controls from 12 Caucasian cohorts. J Med Genet. 2008;45(1):36–42.
  31. Browning BL, Huebner C, Petermann I, Demmers P, McCulloch A, Gearry RB, et al. Association of DLG5 variants with inflammatory bowel disease in the New Zealand Caucasian population and meta-analysis of the DLG5 R30Q variant. Inflamm Bowel Dis. 2007;13:1069–76.
  32. Lin Z, Poritz L, Franke A, Li TY, Ruether A, Byrnes KA, et al. Genetic association of DLG5 R30Q with familial and sporadic inflammatory bowel disease in men. Dis Markers. 2009;27:193–201.
  33. Wang Z, Liu T, Lin Z, Hegarty J, Koltun WA, Wu R. A general model for multilocus epistatic interactions in case-control studies. PLoS One 2010;5:e11384.
  34. Wei Y, Zhenwu L, Ashley AK, John PH, Lisa SP, Yunhua W, et al. Association of a Nkx2-3 polymorphism with Crohn’s disease and expression of Nkx2-3 is up-regulated in B cell lines and intestinal tissues with Crohn’s disease 2009;3:189–95.
  35. Lin Z, Cui X, Li H. Multiplex genotype determination at a large number of gene loci. Proc Natl Acad Sci. USA. 1996;93(6):2582–7.
  36. Biank V, Friedrichs F, Babusukumar U, Wang T, Stoll M, Broeckel U, Kugathasan S. DLG5 R30Q variant is a female-specific protective factor in pediatric onset Crohn’s disease. Am J Gastroenterol. 2007;102:391–8.
  37. Friedrichs F, Henckaerts L, Vermeire S, Kucharzik T, Seehafer T, Moller-Krull M, Bornberg-Bauer E, Stoll M, Weiner J, 3rd. The Crohn’s disease susceptibility gene DLG5 as a member of the CARD interaction network. J Mol Med. 2008;86:423–32.
  38. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31:429–34.
  39. Gabutero E, Moore C, Mallal S, Stewart G, Williamson P. Interaction between allelic variation in IL12B and CCR5 affects the development of AIDS: IL12B/CCR5 interaction and HIV/AIDS. AIDS. 2007;21:65–9.
  40. Moore JH, Williams SM. Epistasis and its implications for personal genetics. Am J Hum Genet. 2009;85:309–20.
  41. Zhang Y, Liu JS. Bayesian inference of epistatic interactions in case-control studies. Nat Genet. 2007;39:1167–73.
  42. Gayan J, Gonzalez-Perez A, Bermudo F, Saez ME, Royo JL, Quintas A, et al. A method for detecting epistasis in genome-wide studies using case-control multi-locus association analysis. BMC Genomics. 2008;9:360.
  43. Torok HP, Glas J, Endres I, Tonenchi L, Teshome MY, Wetzke M, et al. Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn’s disease. Am J Gastroenterol. 2009;104:1723–33.
  44. Glas J, Stallhofer J, Ripke S, Wetzke M, Pfennig S, Klein W, et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol. 2009;104:1737–44.
  45. Achkar JP, Fiocchi C. Gene-gene interactions in inflammatory bowel disease: biological and clinical implications. Am J Gastroenterol. 2009;104:1734–6.